New research has identified three critical findings that reshape our understanding of sex-specific Alzheimer’s risk. First, omega-3 lipid depletion in blood appears to be a reliable marker of cognitive decline specific to women, suggesting that lipid profiling may identify at-risk individuals before symptoms emerge. Second, menopause weakens two essential biochemical pathways—FADS2 and MFSD2A—that regulate brain lipid synthesis and transport, explaining why women’s natural protective advantage erodes after reproductive years end. Third, early omega-3 intervention at doses of 1,000–2,500 mg daily may prevent cognitive decline in healthy women, though current evidence does not support its use as a treatment for established Alzheimer’s disease.
These findings emphasize that prevention timing is critical. Women in midlife should discuss omega-3 supplementation and lipid monitoring with their healthcare providers as potential components of dementia risk reduction strategies. Simply supplementing after cognitive symptoms appear may prove too late to reverse the underlying lipid pathology.
Read the full article on GMJ Newsroom.
Was this article helpful?
